Another Pipeline Diabetes Drug Looks Beneficial

Share this content:
Another Pipeline Diabetes Drug Looks Beneficial
Another Pipeline Diabetes Drug Looks Beneficial
The difference from placebo in hemoglobin (Hb) A1c at 12 weeks with 250 mg per day of remogliflozin was -0.56% (95% CI minus 0.95 to-minus 0.16, P=0.006), according to William O. In contrast, treatment with pioglitazone, 30 mg once daily, had a difference from placebo of minus 0.19% (95% CI minus 0.58-0.20, P=0.337), the researchers reported online in Diabetes, Obesity, and Metabolism.
READ FULL ARTICLE From Medical Page Today
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

is free, fast, and customized just for you!




Already a member?

Sign In Now »